Table 2. Efficacy outcomes.
Outcomes | BECOX population (n=68) |
---|---|
Time to progression, months | |
Median (95% CI) |
11.1 (8.1–14.1) |
Overall survival, months | |
Median (95% CI) |
20.4 (13.2–27.6) |
Best response,
n
(%) | |
Complete | 2 (3) |
Partial | 29 (43) |
Stable disease | 23 (34) |
Progressive disease | 14 (21) |
Overall response rate, % (95% CI) | 45.6 (33.6–58.1) |
Disease-control rate, % (95% CI) |
79.4 (67.6–87.9) |
Confirmed response, n (%) | |
Complete | 2 (3) |
Partial | 21 (31) |
Stable disease | 31 (46) |
Progressive disease | 2 (3) |
Overall response rate, % (95% CI) | 33.8 (23.1–46.4) |
Disease-control rate, % (95% CI) | 79.4 (67.6–87.9) |
Abbreviation: CI=confidence interval.